218 related articles for article (PubMed ID: 36811740)
21. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
[TBL] [Abstract][Full Text] [Related]
22. The randomized, single- and multiple- ascending dose studies of the safety, tolerability, pharmacokinetics of CSPCHA115 in healthy Chinese subjects.
Jing S; Liu W; Yang K; Lin Y; Yao X; Sun G
Clin Transl Sci; 2023 Mar; 16(3):447-458. PubMed ID: 36495036
[TBL] [Abstract][Full Text] [Related]
23. First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of PA9159 Nasal Spray, a Highly Potent Glucocorticoid in Healthy Chinese Volunteers.
Guo S; Hu Y; Wang C; Zhang Y; Wu F; Ni S; Dai Y; Han Y; Hu M; Lu C; Xi Z; Lu L; Zhao X; Zhang L
Eur J Pharm Sci; 2024 Apr; ():106764. PubMed ID: 38599506
[TBL] [Abstract][Full Text] [Related]
24. Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.
Wu J; Zhou R; Zhang Q; Zhang Q; Qin H; Ye Z; Xu Y; Feng S; Shu C; Shen Y; Fan Y; Wang Q; Du Y; Hu W
Diabetes Obes Metab; 2024 Mar; 26(3):901-910. PubMed ID: 38100147
[TBL] [Abstract][Full Text] [Related]
25. The first selective VAP-1 inhibitor in China, TT-01025-CL: safety, tolerability, pharmacokinetics, and pharmacodynamics of single- and multiple-ascending doses.
Yang Y; Yu L; Sheng Z; Lin H; Weng Z; Song W; Cao B; Zhao Y; Gao Y; Ni S; Wang H; Ma T; Huang L; Sun C; Li J
Front Pharmacol; 2024; 15():1327008. PubMed ID: 38741586
[No Abstract] [Full Text] [Related]
26. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP
Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
[TBL] [Abstract][Full Text] [Related]
28. Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects.
Sheng L; Cao W; Lin P; Chen W; Xu H; Zhong C; Yuan F; Chen H; Li H; Liu C; Yang M; Li X
Drug Des Devel Ther; 2021; 15():1101-1110. PubMed ID: 33727798
[TBL] [Abstract][Full Text] [Related]
29. Safety, tolerability, pharmacokinetics and neutrophil elastase inhibitory effects of Sivelestat: A randomized, double-blind, placebo-controlled single- and multiple-dose escalation study in Chinese healthy subjects.
Li K; Dong L; Gao S; Zhang J; Feng Y; Gu L; Yang J; Liu X; Wang Y; Mao Z; Jiang D; Xia Z; Zhang G; Tang J; Ma P; Zhang W
Eur J Pharm Sci; 2024 Apr; 195():106723. PubMed ID: 38336251
[TBL] [Abstract][Full Text] [Related]
30. Safety, tolerability, and pharmacokinetics of oral (S)-oxiracetam in Chinese healthy volunteers: A randomized, double-blind, controlled phase I study.
Zhang T; Tao Y; Pu J; Zhu M; Wan L; Tang C
Eur J Pharm Sci; 2024 Jan; 192():106621. PubMed ID: 37898393
[TBL] [Abstract][Full Text] [Related]
31. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
[TBL] [Abstract][Full Text] [Related]
32. Safety and Pharmacokinetics of Intravenous and Oral Fosmanogepix, a First-in-Class Antifungal Agent, in Healthy Volunteers.
Hodges MR; Ople E; Wedel P; Shaw KJ; Jakate A; Kramer WG; Marle SV; van Hoogdalem EJ; Tawadrous M
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0162322. PubMed ID: 36988461
[TBL] [Abstract][Full Text] [Related]
33. Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase Ⅰ study.
Huang K; Ding Y; Que L; Chu N; Shi Y; Qian Z; Qin W; Chen Y; Gu X; Wang J; Zhang Z; Xu J; He Q
Front Pharmacol; 2022; 13():1057949. PubMed ID: 36408263
[No Abstract] [Full Text] [Related]
34. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
35. A randomized dose-escalation study on the safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of a novel recombinant human albumin in healthy subjects.
Li C; Xiang W; Wu M; Zhang H; Cheng J; Yang T; Mai J; Chi X; Gao X; Ding Y; Niu J
Eur J Pharm Sci; 2021 Oct; 165():105923. PubMed ID: 34229078
[TBL] [Abstract][Full Text] [Related]
36. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
[TBL] [Abstract][Full Text] [Related]
37. Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects.
Sun C; Liu H; Ouyang Z; Ding J; Zhang Q; Ma H; Xu D; Zhang Q; Zhou R; Yang M; Hu W
Expert Opin Investig Drugs; 2024 May; 33(5):533-542. PubMed ID: 38662639
[TBL] [Abstract][Full Text] [Related]
38. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers.
Luk A; Jiang Q; Glavini K; Triyatni M; Zhao N; Racek T; Zhu Y; Grippo JF
Clin Transl Sci; 2020 Sep; 13(5):985-993. PubMed ID: 32268000
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
Ozdarendeli A; Sezer Z; Pavel STI; Inal A; Yetiskin H; Kaplan B; Uygut MA; Bayram A; Mazicioglu M; Unuvar GK; Yuce ZT; Aydin G; Aslan AF; Kaya RK; Koc RC; Ates I; Kara A
Vaccine; 2023 Jan; 41(2):380-390. PubMed ID: 36460536
[TBL] [Abstract][Full Text] [Related]
40. Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.
Shiozaki T; Ueno T; Nagashima H; Yamahira N; Hiraoka M; Eley T; Bifano M; Bertz RJ
Int J Clin Pharmacol Ther; 2015 Apr; 53(4):292-302. PubMed ID: 25740262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
